Bristol Myers Squibb Company’s withdrawal of its supplemental biologics license application for Reblozyl (luspatercept) in anemia in non-transfusion dependent beta-thalassemia may have cost it more than $500m in annual revenues.
BMS Forgoes Thalassemia Label Expansion Revenues For Rebozyl
Withdraws Reblozyl sBLA
The firm was unable to respond to the US FDA’s questions on Reblozyl’s risk-benefit profile in an expanded beta-thalassemia setting and will now focus label expansion efforts elsewhere.
More from Business
• By
In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
More from Scrip
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.